Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.97 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.97 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.97 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | HTR6 | P50406 | 13/20 | 0.55 |
| ▸ | HTR5A | P47898 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pnu-22394 SCHEMBL5364550 | 1.00 | HTR2C (1.00) | HTR2CHTR2AKDM4EALOX15MAPK1 | |
| Pnu-22394 SCHEMBL29779480 | 0.98 | KDM4E (1.00) | HTR2CHTR2AKDM4EALOX15MAPK1 | |
| SCHEMBL30704389 | 0.88 | HTR2A (0.79) | HTR2CHTR2AKDM4EALOX15MAPK1 | |
| SCHEMBL4131362 | 0.88 | HTR2A (0.79) | HTR2CHTR2AKDM4EALOX15MAPK1 | |
| SCHEMBL967629 | 0.88 | HTR2C (0.79) | HTR2CHTR2AKDM4EALOX15MAPK1 | |
| Hydrochloric Acid SCHEMBL31078590 | 0.87 | KDM4E (0.79) | HTR2CHTR2AKDM4EALOX15MAPK1 | |
| Hydrochloric Acid SCHEMBL9057430 | 0.87 | KDM4E (0.79) | HTR2CHTR2AKDM4EALOX15MAPK1 | |
| Hydrochloric Acid SCHEMBL30396890 | 0.87 | KDM4E (0.79) | HTR2CHTR2AKDM4EALOX15MAPK1 | |
| SCHEMBL844491 | 0.80 | HTR2A (0.67) | HTR2CHTR2AKDM4EALOX15MAPK1 | |
| SCHEMBL30223611 | 0.80 | HTR2A (0.67) | HTR2CHTR2AKDM4EALOX15MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| CN-118787751-A | Use of LSD1 inhibitors in combination with drugs for the treatment of cancer | 中国科学院上海药物研究所 | 2024-10-18 | — | — | CN | claimed |
| WO-2024213057-A1 | USE OF COMBINATION OF LSD1 INHIBITOR AND DRUG TO TREAT CANCER | 中国科学院上海药物研究所 | 2024-10-17 | — | — | WO | claimed |
| US-20240226110-A1 | 5-HT2C AGONIST FOR USE IN TREATING CONDITIONS ASSOCIATED WITH CENTRAL HYPOVENTILATION | APNIMED, INC. (DELAWARE) | 2024-07-11 | — | — | US | claimed |
| WO-2023212244-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | claimed |
| WO-2023278597-A1 | 5-HT2C AGONISTS FOR USE IN TREATING CONDITIONS ASSOCIATED WITH CENTRAL HYPOVENTILATION | APNIMED, INC. (DELAWARE) (US) | 2023-01-05 | — | — | WO | claimed |
| US-20220146492-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | SHINE IAN BASIL (US) | 2022-05-12 | — | — | US | claimed |
| EP-3953000-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | Shine, Ian Basil (US) | 2022-02-16 | — | — | EP | claimed |
| WO-2026107229-A1 | REDUCING THE ADDICTIVE LIABILITY OF OPIOID ANALGESICS BY CO- ADMINISTERING 5HT2 RECEPTOR AGONISTS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260053831-A1 | COMPOSITIONS AND METHODS FOR IMPROVING COGNITIVE FUNCTION | DIAMOND THERAPEUTICS INC (CA) | 2026-02-26 | — | — | US | disclosed |
| US-20260053829-A1 | COMPOSITIONS AND METHODS FOR IMPROVING COGNITIVE FUNCTION | DIAMOND THERAPEUTICS INC (CA) | 2026-02-26 | — | — | US | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | disclosed |
| US-20250182901-A1 | SYSTEMS AND METHODS FOR AFFECTING WELL-BEING | DIAMOND THERAPEUTICS INC (CA) | 2025-06-05 | — | — | US | disclosed |
| US-20220244263-A1 | METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | US | disclosed |
| US-20220146492-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | SHINE IAN BASIL (US) | 2022-05-12 | — | — | US | disclosed |
| WO-2022087460-A1 | METHODS FOR IDENTIFYING AND TARGETING THE MOLECULAR SUBTYPES OF ALZHEIMER'S DISEASE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-04-28 | — | — | WO | disclosed |
| US-20220096504-A1 | METHODS AND COMPOSITIONS COMPRISING A 5HT RECEPTOR AGONIST FOR THE TREATMENT OF PSYCHOLOGICAL, COGNITIVE, BEHAVORIAL, AND/OR MOOD DISORDERS | DIAMOND THERAPEUTICS INC. (CA) | 2022-03-31 | — | — | US | disclosed |
| EP-3953000-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | Shine, Ian Basil (US) | 2022-02-16 | — | — | EP | disclosed |
| CN-114040767-A | Methods and compositions comprising 5HT receptor agonists for the treatment of psychological, cognitive, behavioral and/or emotional disorders | 钻石治疗公司 | 2022-02-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260053829-A1 | COMPOSITIONS AND METHODS FOR IMPROVING COGNITIVE FUNCTION | HTR1A, HTR5A, HTR3B | HTR2C 5/4885HTR2A 6/4885KDM4E 4697/4885 |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | HTR2A, HTR5A, HTR6 | HTR2C 5/4885HTR2A 1/4885KDM4E 4347/4885 |
| US-20240226110-A1 | 5-HT2C AGONIST FOR USE IN TREATING CONDITIONS ASSOCIATED WITH CENTRAL HYPOVENTILATION | HTR2C, HTR5A, HTR1A | HTR2C 1/4885HTR2A 5/4885KDM4E 2994/4885 |
| US-20220096504-A1 | METHODS AND COMPOSITIONS COMPRISING A 5HT RECEPTOR AGONIST FOR THE TREATMENT OF PSYCHOLOGICAL, COGNITIVE, BEHAVORIAL, AND/OR MOOD DISORDERS | HTR1A, HTR2B, HTR7 | HTR2C 5/4885HTR2A 6/4885KDM4E 1101/4885 |
| US-20260053831-A1 | COMPOSITIONS AND METHODS FOR IMPROVING COGNITIVE FUNCTION | HTR1B, HTR2B, HTR3B | HTR2C 4/4885HTR2A 9/4885KDM4E 4767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.